The risk of diabetic retinopathy progressing is lower when taking empagliflozin for type 2 diabetes.

Published Date: 29 Jun 2023

Results from the EMPRISE study, which were presented at ADA 2023, revealed empagliflozin was linked to a 23 percent lower risk of diabetic retinopathy progression in adults with T2D.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot